Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624915 | 0.93 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL16624910 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL16624893 | 0.85 | MEN1 (0.48) | SMN1; SMN2LMNANPC1TSHRCYP3A4 | |
| SCHEMBL16624896 | 0.84 | SLC22A1 (0.42) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL19071744 | 0.79 | GAA (0.42) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL16624926 | 0.79 | KCNA5 (0.58) | SMN1; SMN2LMNATSHRCYP3A4ALDH1A1 | |
| SCHEMBL16624901 | 0.79 | F2 (0.46) | LMNANPC1RAB9ATSHRCYP3A4 | |
| SCHEMBL5668366 | 0.78 | NPC1 (0.64) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL14680082 | 0.78 | NPC1 (0.56) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL16624902 | 0.78 | L3MBTL1 (0.53) | SMN1; SMN2LMNANPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864284-B1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO KGAA (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9458081-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9458081-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150099809-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150099809-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA (DE) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099809-A1 | PHOTOLABILE PRO-FRAGRANCES | TRPA1, PSAP, CRY1 | SMN1; SMN2 2584/4885LMNA 1058/4885NPC1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.